Can I Take Vitamin B6 with Rapamycin (Sirolimus)?

What Is the Interaction Between Vitamin B6 and Rapamycin?

There is no documented pharmacokinetic interaction between vitamin B6 and rapamycin. Sirolimus is metabolized primarily by hepatic and intestinal CYP3A4 and is a substrate of P-glycoprotein (P-gp). Vitamin B6, at the doses found in food or standard multivitamins, does not inhibit or induce either pathway [1].

The concern that does exist is pharmacodynamic and is not specific to rapamycin. High-dose B6 supplementation causes sensory peripheral neuropathy independent of whatever else a patient is taking. Because rapamycin itself can cause adverse neurological events in a small subset of patients, the co-occurrence of B6-related neuropathy could complicate clinical evaluation.

How Rapamycin Is Metabolized

Sirolimus is absorbed orally and undergoes extensive first-pass metabolism. CYP3A4 enzymes in the gut wall and liver are the primary metabolic route. P-glycoprotein in the intestinal epithelium also limits absorption by pumping sirolimus back into the gut lumen [2]. Any compound that inhibits CYP3A4 (such as ketoconazole or grapefruit juice) raises sirolimus blood levels; inducers like rifampin sharply lower them [2].

Pyridoxine (B6) does not fit either category. Published in vitro and clinical pharmacology data show no meaningful CYP3A4 modulation at the doses used in dietary supplements [3].

How Vitamin B6 Is Processed

Pyridoxine is converted in the liver to pyridoxal-5-phosphate (PLP), the biologically active coenzyme form. PLP participates in over 100 enzymatic reactions, including amino acid transamination and neurotransmitter synthesis [4]. It is water-soluble, and excess amounts are excreted renally, but accumulation can still occur at high supplemental doses because pyridoxine itself (before conversion) is neurotoxic to dorsal root ganglia at elevated concentrations [5].

Does Vitamin B6 Affect Sirolimus Blood Levels?

No. Sirolimus trough concentrations are not expected to change with vitamin B6 co-administration. The FDA-approved prescribing information for sirolimus (Rapamune, NDA 021083) lists strong CYP3A4 inhibitors and inducers as the drug interactions requiring dose adjustment [2]. Pyridoxine is absent from that list, and no published pharmacokinetic study has detected an interaction.

CYP3A4 and P-gp: The Two Gatekeepers

The clinical importance of the CYP3A4/P-gp axis for sirolimus is well-documented. A trial by Zimmerman et al. Showed that rifampin, a potent CYP3A4 inducer, reduced sirolimus AUC by approximately 82% in healthy volunteers [6]. Conversely, ketoconazole increased sirolimus Cmax by roughly 4-fold [2]. These interactions are the reason transplant programs monitor sirolimus trough levels every 5 to 7 days after any medication change.

Pyridoxine produces no such effect. A comprehensive review of pyridoxine pharmacology published in the American Journal of Clinical Nutrition found no evidence of clinically significant cytochrome P450 modulation by B6 vitamers at doses up to 100 mg/day [3].

What This Means in Practice

Patients on rapamycin for transplant rejection prophylaxis or off-label longevity protocols do not need to adjust their sirolimus dose when adding B6 at typical supplement levels (10 to 25 mg/day). Trough monitoring should continue on its existing schedule, not at an accelerated frequency.

What Is the Real Risk: High-Dose B6 Neuropathy

The genuine clinical issue is B6 toxicity, not a drug interaction. Sensory peripheral neuropathy from pyridoxine was described as early as 1983 by Schaumburg et al. In the New England Journal of Medicine, who reported seven patients developing severe sensory neuropathy after taking 2 to 6 g/day for 2 to 40 months [5]. Later cases confirmed that toxicity can appear at much lower doses when intake is sustained.

Dose-Dependent Neuropathy Risk

The European Food Safety Authority (EFSA) set a tolerable upper intake level (UL) for B6 at 25 mg/day for adults in 2023, down from the previous 25 mg/day level, citing case reports of neuropathy at chronic intakes of 1 to 6 mg/day in some individuals [7]. The U.S. National Institutes of Health Office of Dietary Supplements places the UL at 100 mg/day for adults, acknowledging that the evidence base for lower thresholds remains under review [4].

Symptoms include:

• Numbness and tingling, typically starting in the feet
• Gait instability
• Loss of position sense
• Reduced deep tendon reflexes

Most cases are reversible on discontinuation, though recovery can take 6 months or longer [5].

Why This Matters on a Rapamycin Regimen

Rapamycin inhibits mTORC1, which is central to protein synthesis and cellular autophagy. In rare cases, sirolimus-associated pneumonitis and peripheral edema are reported adverse events [2], and any new neurological complaint in a sirolimus patient triggers a differential that could include drug toxicity. Adding high-dose B6 introduces an independent neuropathy risk that may make that differential harder to sort out.

The practical instruction: keep B6 supplementation at or below 25 mg/day if you are on any complex medication regimen, and report new tingling, numbness, or balance changes to your prescriber immediately.

Rapamycin Pharmacology: Context for Supplement Decisions

Understanding why rapamycin has a narrow therapeutic index helps explain why its drug interaction list is taken seriously, even when the supplement in question (like B6) does not appear on it.

mTOR Inhibition and the Longevity Use Case

Rapamycin binds FKBP12 to form a complex that inhibits mTORC1, reducing downstream signaling through S6K1 and 4E-BP1 [8]. This pathway controls cell growth, autophagy, and senescent cell accumulation. The ITP (Interventions Testing Program) study in mice showed lifespan extension of 9 to 14% in male and female mice when rapamycin was started at 20 months of age [9]. Those preclinical results drove widespread off-label human use, typically at 1 to 6 mg once weekly.

No large randomized controlled trial has established an optimal longevity dose in humans. The PEARL trial (NCT04488601) and several smaller pilots are ongoing, but clinicians prescribing off-label rely on transplant pharmacokinetic data scaled to intermittent dosing.

Narrow Therapeutic Window and Trough Monitoring

For solid organ transplant recipients, sirolimus trough targets are 4 to 12 ng/mL in the maintenance phase, as specified in the Rapamune prescribing information [2]. Troughs below 4 ng/mL risk rejection; troughs consistently above 15 ng/mL raise the risk of infections, impaired wound healing, and thrombocytopenia.

The narrow window means even modest CYP3A4 interactions can matter. Grapefruit juice, for example, increased sirolimus AUC by 350% in one crossover study [2]. B6 has no such effect, but this context explains why patients on sirolimus are advised to scrutinize every supplement before adding it.

Vitamin B6: Clinical Benefits and Why People Take It

Pyridoxine is one of the most commonly purchased single-nutrient supplements in the United States. Deficiency, though uncommon in well-nourished adults, causes dermatitis, glossitis, and peripheral neuropathy [4]. Several conditions and medications genuinely deplete B6.

Conditions That Increase B6 Demand

Isoniazid (used for tuberculosis) chelates pyridoxal phosphate and causes B6-depletion neuropathy. Standard co-prescribing practice is pyridoxine 25 to 50 mg/day alongside isoniazid [10]. Hydralazine, penicillamine, and cycloserine work by similar mechanisms and carry the same co-prescribing recommendation.

Rapamycin is not in this category. It does not deplete or antagonize pyridoxine through any known mechanism. A patient on rapamycin alone, without isoniazid or similar agents, has no clinical reason to take high-dose B6 unless they have documented deficiency.

Dietary Reference Values

The Recommended Dietary Allowance (RDA) for B6 is 1.3 mg/day for adults aged 19 to 50, rising to 1.5 mg/day for women and 1.7 mg/day for men over 50 [4]. Most standard multivitamins contain 2 to 10 mg. High-dose single-nutrient B6 supplements are available at 50 to 500 mg per tablet, and it is this end of the range that carries neuropathy risk.

Practical Guidance for Patients on Rapamycin Considering B6

The decision framework below applies to patients taking rapamycin (any dose or frequency) who want to add or continue vitamin B6 supplementation.

Step 1: Establish Your Reason for Taking B6

Ask whether you have a documented deficiency (serum PLP below 20 nmol/L is the standard cut-off), are taking isoniazid or hydralazine, or are simply supplementing for general wellness. If you have no documented deficiency and are not on a B6-depleting drug, a standard multivitamin providing 2 to 10 mg/day is sufficient.

Step 2: Confirm Your B6 Dose Is Below the Safety Threshold

At 25 mg/day or less, no pharmacokinetic or pharmacodynamic interaction with sirolimus is expected, and the risk of B6-induced neuropathy is very low. Doses above 50 mg/day have no established benefit over lower doses for healthy adults and carry documented neuropathy risk with prolonged use [5, 7].

Step 3: Continue Standard Sirolimus Monitoring

Trough monitoring schedules do not need to change when adding B6. Maintain your existing draw frequency. If your trough shifts unexpectedly, B6 is not the likely culprit; review other medication changes first.

Step 4: Report Neurological Symptoms Promptly

Any new tingling, numbness, unsteadiness, or burning sensation should be reported to your prescriber without waiting for the next scheduled visit. Both sirolimus and high-dose B6 can cause peripheral symptoms through separate mechanisms, and distinguishing between them requires clinical evaluation, not self-management.

What Other Supplements Interact With Rapamycin?

B6 is one of the safer supplements to combine with rapamycin. Several others carry documented or probable interactions that require more caution.

Supplements That May Raise Sirolimus Levels

• St. John's Wort: A potent CYP3A4 inducer. Co-administration sharply lowers sirolimus AUC; transplant programs explicitly contraindicate it [2].
• Grapefruit and grapefruit juice: Furanocoumarins in grapefruit irreversibly inhibit intestinal CYP3A4, raising sirolimus exposure by as much as 350% [2].
• Black pepper extract (piperine): Inhibits CYP3A4 and P-gp at doses used in bioavailability-enhancing supplements. Human PK data are limited but consistent with an interaction [11].

Supplements With Low Interaction Risk

Magnesium glycinate, vitamin D3, omega-3 fatty acids (fish oil), and standard-dose multivitamins are not CYP3A4 modulators and carry no documented pharmacokinetic interaction with sirolimus [3]. Low-dose B6 (under 25 mg/day) belongs in this lower-risk group.

Monitoring Summary for Patients on Rapamycin

Regardless of which supplements a patient takes, the following monitoring applies based on the FDA prescribing information and transplant nephrology guidelines [2, 12]:

| Parameter | Frequency | Target | |---|---|---| | Sirolimus whole-blood trough | Every 5 to 7 days after any dose or drug change; monthly when stable | 4 to 12 ng/mL (transplant) | | CBC with differential | Monthly for first 3 months, then quarterly | WBC, platelets | | Lipid panel | Every 3 months initially | LDL, triglycerides | | Serum creatinine | Monthly | Baseline-dependent | | Neurological symptom review | Every clinic visit | None new |

Patients taking B6 above 25 mg/day should add a brief neurological symptom check at each visit: ask about tingling, numbness in extremities, and balance changes.